145 related articles for article (PubMed ID: 23600509)
1. Establishment and characterization of a novel anti-DNAM-1 monoclonal antibody.
Yamashita Y; Abe F; Hirochika R; Tahara-Hanaoka S; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2013 Feb; 32(1):60-4. PubMed ID: 23600509
[TBL] [Abstract][Full Text] [Related]
2. Development and Characterization of Novel Monoclonal Antibodies Against Human DNAM-1.
Okumura G; Abe F; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):135-139. PubMed ID: 28498033
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
[TBL] [Abstract][Full Text] [Related]
4. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice.
Nagumo Y; Iguchi-Manaka A; Yamashita-Kanemaru Y; Abe F; Bernhardt G; Shibuya A; Shibuya K
PLoS One; 2014; 9(11):e112415. PubMed ID: 25384044
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands.
Tahara-Hanaoka S; Miyamoto A; Hara A; Honda S; Shibuya K; Shibuya A
Biochem Biophys Res Commun; 2005 Apr; 329(3):996-1000. PubMed ID: 15752754
[TBL] [Abstract][Full Text] [Related]
6. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A
J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096
[TBL] [Abstract][Full Text] [Related]
7. Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice.
Nabekura T; Shibuya K; Takenaka E; Kai H; Shibata K; Yamashita Y; Harada K; Tahara-Hanaoka S; Honda S; Shibuya A
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18593-8. PubMed ID: 20937876
[TBL] [Abstract][Full Text] [Related]
8. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.
Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A
Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800
[TBL] [Abstract][Full Text] [Related]
9. DNAM-1 controls NK cell activation via an ITT-like motif.
Zhang Z; Wu N; Lu Y; Davidson D; Colonna M; Veillette A
J Exp Med; 2015 Nov; 212(12):2165-82. PubMed ID: 26552706
[TBL] [Abstract][Full Text] [Related]
10. A lymphocyte differentiation and activation antigen, CZ-1, that distinguishes between CD8+ and unstimulated CD4+ T lymphocytes.
Vargas-Cortes M; O'Donnell CL; Appel MC; Maciaszek JW; Yurkunas KS; Welsh RM
Eur J Immunol; 1992 Apr; 22(4):1043-7. PubMed ID: 1348027
[TBL] [Abstract][Full Text] [Related]
11. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.
Tahara-Hanaoka S; Shibuya K; Kai H; Miyamoto A; Morikawa Y; Ohkochi N; Honda S; Shibuya A
Blood; 2006 Feb; 107(4):1491-6. PubMed ID: 16249389
[TBL] [Abstract][Full Text] [Related]
12. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
13. The Role of T Cell Costimulation via DNAM-1 in Kidney Transplantation.
Kraus AK; Chen J; Edenhofer I; Ravens I; Gaspert A; Cippà PE; Mueller S; Wuthrich RP; Segerer S; Bernhardt G; Fehr T
PLoS One; 2016; 11(2):e0147951. PubMed ID: 26840537
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK-mediated killing of immature dendritic cells.
Seth S; Georgoudaki AM; Chambers BJ; Qiu Q; Kremmer E; Maier MK; Czeloth N; Ravens I; Foerster R; Bernhardt G
J Leukoc Biol; 2009 Jul; 86(1):91-101. PubMed ID: 19380711
[TBL] [Abstract][Full Text] [Related]
15. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.
Chan CJ; Andrews DM; McLaughlin NM; Yagita H; Gilfillan S; Colonna M; Smyth MJ
J Immunol; 2010 Jan; 184(2):902-11. PubMed ID: 20008292
[TBL] [Abstract][Full Text] [Related]
16. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
18. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors.
Gilfillan S; Chan CJ; Cella M; Haynes NM; Rapaport AS; Boles KS; Andrews DM; Smyth MJ; Colonna M
J Exp Med; 2008 Dec; 205(13):2965-73. PubMed ID: 19029380
[TBL] [Abstract][Full Text] [Related]
19. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
20. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
